Top Takeaways:
- Shionogi & Co. will acquire Japan Tobacco’s pharmaceutical business through an absorption-type company split effective Dec. 25, 2025.
- The deal is intended to expand Shionogi’s product portfolio and strengthen its market presence in healthcare.
- Japan Tobacco will exit the pharmaceutical sector as Shionogi integrates the operations.
Shionogi & Co., Ltd. announced it has signed an absorption-type company split agreement with Japan Tobacco Inc. to acquire JT’s pharmaceutical business, with the transaction scheduled to take effect on Dec. 25, 2025.
The Osaka-based drugmaker said the strategic acquisition will expand its pipeline and market reach by incorporating Japan Tobacco’s pharmaceutical operations. JT, which has been scaling back its non-tobacco units, will fully exit the pharma sector as a result.
“By integrating JT’s pharmaceutical business, Shionogi will strengthen its capabilities to deliver innovative treatments and broaden its impact in healthcare,” the company said in a statement.
Shionogi is best known for developing and marketing antibiotics, antivirals and treatments in infectious disease and central nervous system disorders. The acquisition is expected to bolster its research and commercial footprint while reinforcing its commitment to addressing unmet medical needs.
Financial details of the deal were not disclosed.
